Author:
Naritaka Hiroyuki,Aoki Yoshitaka,Obata Yukako,Mimuro Soichiro,Nakajima Yoshiki
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs;Graham DJ;JAMA,2004
2. FDA drug safety communication. important safety label changes to cholesterol-lowering statin drugs. (2016). Accessed: September 4, 2023: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-c....
3. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials;Cholesterol Treatment Trialists' Collaboration;Lancet,2022
4. Rhabdomyolysis and statins: a pharmacovigilance comparative study between statins;Montastruc JL;Br J Clin Pharmacol,2023
5. Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients;Davis JW;BMJ Open,2021